Related Experiment Video
Updated: May 16, 2026

Differentiation and Characterization of Neural Progenitors and Neurons from Mouse Embryonic Stem Cells
Published on: May 15, 2020
Embryonic stem cell-based screen for small molecules: cluster analysis reveals four response patterns in developing
1Department of Pediatrics, Geneva University Hospital, Geneva, Switzerland. ilse.kern@hcuge.ch
Abstract:
Neural differentiation of embryonic stem cells (ESC) is considered a promising model to perform in vitro testing for neuroactive and neurotoxic compounds. We studied the potential of a dual reporter murine ESC line to identify bioactive and/or toxic compounds. This line expressed firefly luciferase under the control of the neural cell-specific tubulin alpha promoter (TUBA1A), and renilla luciferase under the control of the ubiquitous translation elongation factor 1-alpha-1 (EEF1A1) promoter. During neural differentiation, TUBA1A activity increased, while EEF1A1 activity decreased. We first validated our test system using the known neurotoxin methyl mercury. This compound altered expression of both reporter genes, with ESC-derived neural precursors being affected at markedly lower concentrations than undifferentiated ESCs. Analysis of a library of 1040 bioactive compounds picked up 127 compounds with altered EEF1A1 and/or TUBA1A promoter activity, which were classified in 4 clusters. Cluster 1 (low EEF1A1 and TUBA1A) was the largest cluster, containing many cytostatic drugs, as well as known neurodevelopmental toxicants, psychotropic drugs and endocrine disruptors. Cluster 2 (high EEF1A1, stable TUBA1A) was limited to three sulfonamides. Cluster 3 (high EEF1A1 and TUBA1A) was small, but markedly enriched in neuroactive and neurotoxic compounds. Cluster 4 (stable EEF1A1, high TUBA1A) was heterogeneous, containing endocrine disruptors, neurotoxic and cytostatic drugs. The dual reporter gene assay described here might be a useful addition to in vitro drug testing panels. Our two-dimensional testing strategy provides information on complex response patterns, which could not be achieved by a single marker approach.
Insights
This study developed a dual reporter embryonic stem cell (ESC) line for in vitro testing of neuroactive and neurotoxic compounds. The system effectively identified bioactive compounds and provided complex response patterns for enhanced drug safety assessment.
Area of Science:
- Stem cell biology
- Neuroscience
- Toxicology
Background:
- Embryonic stem cells (ESCs) offer a promising in vitro model for testing neuroactive and neurotoxic compounds.
- Current in vitro testing methods may lack the sensitivity to detect complex responses to various bioactive substances.
Purpose of the Study:
- To evaluate a dual reporter murine ESC line for identifying bioactive and toxic compounds.
- To assess the utility of this system in detecting neuroactive and neurotoxic effects during neural differentiation.
Main Methods:
- Developed a dual reporter ESC line with firefly luciferase under the neural-specific TUBA1A promoter and renilla luciferase under the ubiquitous EEF1A1 promoter.
- Validated the system using methyl mercury, a known neurotoxin, and analyzed a library of 1040 bioactive compounds.
- Classified compounds based on altered reporter gene activities (EEF1A1 and TUBA1A) into four distinct clusters.
Main Results:
- The dual reporter system detected neurotoxic effects of methyl mercury at lower concentrations in differentiating ESCs compared to undifferentiated cells.
- Analysis of 1040 compounds identified 127 with altered reporter gene activity, categorized into four clusters.
- Cluster 3, characterized by high EEF1A1 and TUBA1A activity, was significantly enriched in neuroactive and neurotoxic compounds.
Conclusions:
- The dual reporter gene assay is a valuable addition to in vitro drug testing panels.
- This two-dimensional testing strategy provides nuanced information on complex compound responses, surpassing single-marker approaches.
- The system aids in identifying potential neurodevelopmental toxicants, psychotropic drugs, and endocrine disruptors.

